Navigation Links
Misonix Announces Achievement of Contract Vendor Status With Select Medical Corporation
Date:11/16/2010

FARMINGDALE, N.Y., Nov. 16, 2010 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has announced its achievement of contract vendor status with Select Medical Corporation, based in Mechanicsburg, PA, for its SonicOne® Ultrasonic Wound Cleansing and Debridement System. As a result of this status, specialty hospitals, without further approval, can easily arrange for system valuations and issue purchase orders for disposable products, accessories and system rentals.  

Select Medical Corporation is an operating unit of Select Medical Holdings (NYSE: SEM), a leading operator of specialty hospitals, including 111 Long Term Acute Care ("LTACH") facilities and 6 Acute Rehabilitation facilities located in 28 states.  These facilities operate as Select Specialty Hospitals, Regency Specialty Hospitals and Great Lakes Specialty Hospitals.  Select also operates approximately 950 Out Patient Rehabilitation Clinics in 36 states and provides contract Medical Rehabilitation Services to over 400 skilled nursing, assisted living, senior care, school and worksite locations.  Misonix's contract vendor status is focused on the LTACH facilities, which provide care and rehabilitation for trauma victims and other serious and complex medical conditions.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures.  The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix is excited by the potential for expanded clinical use of our ultrasonic wound management technology via an association with a high caliber organization such as Select Medical," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "The clinical benefits for patient and physician over traditional means of wound cleansing and debridement are evident.  This is another example of our commitment to state-of-the-art medical devices for use by the worldwide medical community working in cooperation with highly regarded healthcare providers."

About Misonix:Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.Investor Relations Contact:Kevin McGrath/Cameron Associates, Inc.212-245-4577Kevin@cameronassoc.com
'/>"/>

SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
3. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
4. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
5. Misonix Announces New Distribution Agreement for Mexico
6. Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern
7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
8. Misonix Announces New Distribution Agreement for Peru
9. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
10. Misonix Announces New Distribution Agreement for Argentina
11. Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
(Date:4/18/2017)... 18, 2017  Socionext Inc. and SOINN Inc. ... 2016, in which Socionext extracts and delivers biometrics ... achieved initial results in reading ultrasound images from ... SOINN. The results will be introduced at Medtec ... at booths 4505 & 4507. In ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will be ... to publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is an ... Medicine. He also serves as Medical Director for the Bureau of Emergency Medical Services ...
(Date:4/24/2017)... ... ... Emmanuel College is introducing enhancements to its RN-to-BSN Degree Program ... of 2017, Emmanuel’s program will allow registered nurses (RN)s to earn a Bachelor of ... little as $14,528. These changes will enable nurses to complete their degree in a ...
(Date:4/24/2017)... ... 2017 , ... Ridgecrest Herbals makes it a point to lead the Utah ... and support renewable energy. They believe this is a crucial part of their mission ... health issues, and maintain that destroying the environment in the pursuit of profit is ...
(Date:4/24/2017)... ... 2017 , ... Today, Bright Pink , a national non-profit organization focusing on the prevention ... , Bright Pink is proud to announce Katie Thiede as their new Chief Executive ... role as Chairman of the Board and launched a national search to find a ...
(Date:4/24/2017)... ... April 24, 2017 , ... The John P. McGovern Museum ... allows anyone, anywhere to track their cognitive health, and share results with their physicians. ... brain health on the museum's website. , BrainCheck founder, Dr. David Eagleman, formerly at ...
Breaking Medicine News(10 mins):